ifetroban
·Code: CPI-IFE-007
ifetroban: developed by 1 company · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | Phase 2 |
FDA Decisions
FDA_MeetingFDA granted Orphan Drug Designation and Rare Pediatric Disease Designation for Ifetroban for cardiomyopathy associated with Duchenne muscular dystrophy.(CPIX)
Frequently asked questions
Who is developing ifetroban?
ifetroban is being developed by CUMBERLAND PHARMACEUTICALS INC.
What is ifetroban's latest FDA decision?
The most recent tracked FDA decision for ifetroban is FDA_Meeting for FDA granted Orphan Drug Designation and Rare Pediatric Disease Designation for Ifetroban for cardiomyopathy associated with Duchenne muscular dystrophy., dated November 6, 2024.
Get deeper analysis on ifetroban
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis